The FDA has approved veligrotug-vvze (Lumvoa; Viridian Therapeutics, Waltham, MA, USA) for the treatment of thyroid eye disease (TED), regardless of disease activity or duration.

This week in ophthalmology: expert pearls on posterior capsule opacification after cataract surgery, new clinical data for MHB018A in thyroid eye disease, uncontrolled blood pressure in patients with diabetes attending retina care, practical B-scan ultrasound guidance for retina clinics, and the opening of the 40th World Ophthalmology Congress in Prague. Here are five stories to catch up on this week.

Updated Phase I/II data presented at ENDO 2026 suggest subcutaneous MHB018A was associated with proptosis and diplopia responses in patients with active and chronic thyroid eye disease.

Dr Joobin Khadamy (Capio Globen Eye Clinic, Stockholm) shares his practical considerations involved in managing PCO after cataract surgery. In this Q&A, Dr Khadamy discusses when to consider Nd:YAG capsulotomy, situations in which treatment should be delayed, technical pearls for capsulotomy, higher-risk patient groups and strategies to reduce the risk or severity of PCO at the time of cataract surgery.

B-scan ultrasonography is a valuable imaging tool in retina practice, particularly when direct visualization of the posterior segment is limited by media opacity, trauma, or other clinical factors. It can provide important structural and dynamic information about the vitreous, retina, choroid, optic nerve, and posterior segment lesions, helping clinicians refine diagnosis, assess urgency, and monitor disease over time. We spoke with Dr Mohan about when B-scan is most useful, how to structure the assessment, and practical ways to improve image quality and diagnostic confidence in a busy retina clinic.

Belite Bio has completed its New Drug Application submission to the FDA for tinlarebant, an investigational oral treatment being developed for Stargardt disease type 1.

This week in ophthalmology: robotic-assisted vitreoretinal surgery, a completed NDA submission for tinlarebant in Stargardt disease type 1, changing treatment patterns in retinopathy of prematurity, FDA acceptance of the resubmitted BLA for ONS-5010/LYTENAVA™ in wet AMD, and where AI may add value beyond image analysis. Here are five stories to catch up on this week.

As artificial intelligence (AI), data science, and real-world evidence become increasingly important across ophthalmology, their potential is expanding beyond image analysis alone. From identifying clinical phenotypes in heterogeneous conditions such as dry eye disease to supporting risk stratification, patient education, and more personalized follow-up care, these approaches may help clinicians interpret complex data and improve decision-making in everyday practice. We spoke with Dr Germán Mejía-Salgado (Universidad Autónoma de Bucaramanga, Bucaramanga, Colombia) about how AI and real-world clinical data are being explored in ophthalmology, where these tools could add the most value beyond diagnostic imaging, and what will be needed for AI to become genuinely useful for ophthalmologists and their patients.

The FDA has accepted Outlook Therapeutics’ resubmitted biologics license application for bevacizumab-vikg (LYTENAVA™; Outlook Therapeutics, Inc., Iselin, NJ, USA) for the treatment of neovascular, or wet, age-related macular degeneration (AMD). The application has been classified as a Class 1 review, with a Prescription Drug User Fee Act target action date of July 29, 2026.1